Impact of Anemia & Hemolysis in Sickle Cell Disease

Expert hematologists review the presentation and diagnosis of sickle cell disease and the resulting effect of anemia and hemolysis on a patient’s quality of life.

Jeffrey D. Lebensburger, DO, MSPH, and John J. Strouse, MD, PhD, comment on the serious complications of anemia and hemolysis caused by sickle cell disease and the impact on pediatric patients vs adults.

Sophie M. Lanzkron, MD, MHS, and Jeffrey D. Lebensburger, DO, MSPH, review the underlying pathophysiology of acute multisystem organ failure and resulting cerebrovascular and neurologic complications associated with sickle cell disease.

Dr John J. Strouse leads the discussion on pulmonary complications that can arise because of sickle cell disease.

Sophie M. Lanzkron, MD, MHS, and Jeffrey D. Lebensburger, DO, MSPH, comment on renal complications and outcomes that can result from sickle cell disease.

Experts in hematology discuss NHLBI guideline recommendations for the screening and monitoring of anemia-related disease manifestations as well as goals of therapy for patients with sickle cell disease.

Jeffrey D. Lebensburger, DO, MSPH, reviews data and key findings from the 72-week analysis of the HOPE study using voxelotor for patients with sickle cell disease.

John J. Strouse, MD, PhD, and Sophie M. Lanzkron, MD, MHS, discuss the real-world significance of voxelotor for the treatment of sickle cell disease.

Expert hematologists comment on the use of crizanlizumab in reducing painful crisis frequency in sickle cell disease and share their experience with the drug in clinical practice.

Drs Sophie M. Lanzkron, Jeffrey D. Lebensburger, and John J. Strouse, share insights on the safety profile and cost of gene therapy for the management of sickle cell disease.

Experts in hematology address unmet needs and precautions patients can take to avoid complications of sickle cell disease.

Sophie M. Lanzkron, MD, MHS; Jeffrey D. Lebensburger; and John J. Strouse, MD, PhD, share key takeaways and closing thoughts for the management of sickle cell disease.